Clinical Trials

316 enrolled

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04685070 2024-08-14

Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer

56 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06463171 2024-06-17

Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06452433 2024-06-11

Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.

91 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06300424 2024-04-17

NEOVADE

Phase 2 Recruiting

32 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05946460 2024-02-06

Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.

22 enrolled

Lung Neoplasms

NCT06185400 2023-12-29

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

108 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04401059 2023-12-27

SELECT-2

Phase 4 Recruiting

744 enrolled

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT06102928 2023-10-26

A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation

Phase NA Recruiting

30 enrolled

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

NCT06043973 2023-09-21

Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

Phase 3 Recruiting

98 enrolled

Advanced Non-small Cell Lung Cancer

NCT05994339 2023-08-29

Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer

Phase 2/3 Unknown

40 enrolled

Lung Neoplasms

NCT05826483 2023-04-24

Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status

Phase 1 Unknown

20 enrolled

Lung Neoplasms

NCT04922138 2023-04-21

APPOINT

104 enrolled

Lung Neoplasms

NCT05800223 2023-04-05

Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer

Phase 3 Recruiting

300 enrolled

Non-small Cell Lung Cancer Metastatic

NCT04519983 2023-03-20

Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs

40 enrolled

Lung Neoplasms

NCT05768490 2023-03-14

Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases

Phase 3 Recruiting

232 enrolled

CNS

Brain Neoplasms

NCT04755738 2021-09-05

MWA

234 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04978753 2021-07-27

the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer

54 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04952168 2021-07-07

Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

26 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04944069 2021-06-29

ATTRACT

Phase NA Unknown

69 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT04905550 2021-06-02

Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC

50 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04882345 2021-05-11

ACTIVE

40 enrolled

Lung Neoplasms

NCT04643847 2020-11-25

A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases

47 enrolled

CNS

Brain Neoplasms

NCT04500704 2020-08-05

ACROSS1

Phase 3 Unknown

166 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04500717 2020-08-05

ACROSS2

Phase 3 Unknown

460 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04455594 2020-07-02

ANSWER

168 enrolled